Latest Interviews
"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."
59206
"We are absolutely thrilled to have successfully completed an A$130 million two-tranche placement with no debt. Abujar is now fully funded to commence production in late CY2022."
59197
"ASPRI will continue to work closely with knowledge partners and various Singapore economic agencies to educate our members and seek opportunities to pilot and testbed emerging solutions which have scalability potential in the low-carbon future."
59195
“It is essential to find ways to improve the use of the mining canon and royalties, to strengthen institutional capacities, to speed up the execution of projects and to achieve greater transparency.”
59193
"We pride ourselves in being a discovery engine that will hopefully build out a large portfolio of new chemical entities that can one day become marketed drugs."
59191
"The past 12 months have been busy as we have seen a significant amount of new company formations, which require accounting, tax advisory and structuring support."